LI. + + + + R=0 .6304 p<0.0001 0 50 100 150 200 Total tumor measurement (% of day 1 cycle 1) Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 APPENDIX B I mmune -related Response Criteria (irRC) Quick Reference Page 81 Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Comparison between RECIST 1.1 criteria and the irRC * RECIST 1.1 irRC RECIST 1.1 New, measurable lesions Always represent PD Incorporated into tumor burden New, non- measurable lesions Always represent PD Does not define progression (but precludes irCR) Non-index lesions Changes contribute to defining best overall response (BOR) of CR, PR, SD, and PD Contribute to defining irCR (complete disappearance required) CR Disappearance of all lesions in two consecutive observations not less than 4 week apart Disappearance of all lesions in two consecutive observations not less than 4 week apart if single arm trial and primary endpoint only PR >30% decrease in the sum of the diameters of all index lesions compared with baseline in two observations at least 4 week apart, in absence of new lesions or unequivocal progression of non-indexlesions≥ 30% decrease in tumor burden compared with baseline in two observations at least 4 week apart if single arm trial and primary endpoint only SD < 30% decrease in sum of longest diameters of all index lesions compared with baseline cannot be established nor < 20% increase compared with nadir, in the absence of new lesions or unequivocal progression of non-index lesions < 30% decrease in tumor burden compared with baseline cannot be established nor < 20% increase compared with nadir PD At least 20% increase in the sum of the longest diameters of index lesions and/ or unequivocal progression of non-index lesions At least 20% increase in tumor burden compared with nadir (at any single time point) in two consecutive observations at least 4 week apart Handling of lymph nodes Lymph nodes are considered pathologically enlarged if >10 mm in SAD. To be measurable, nodal lesions must be ≥ 15 mm in SAD.